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Received January 27, 2012; accepted September 21, 2012AbstractBackground: The Taiwanese government has proposed a population-based colorectal tumor detection program for the average-risk population.
This study’s objectives were to understand the outcomes of these screening policies and to evaluate the effectiveness of the program.
Methods: We compared two databases compiled in one medical center. The “policy-promoted cancer screening” (PPS) database was built on the
basis of the policy of the Taiwan Bureau of National Health Insurance for cancer screening. The “health promotion service” (HPS) database was
built to provide health check-ups for self-paid volunteers. Both the PPS and HPS databases employ the immunochemical fecal occult blood test
(iFOBT) and colonoscopy for colorectal tumor screening using different strategies. A comparison of outcomes between the PPS and HPS
included: (1) quality indicatorsdcompliance rate, cecum reaching rate, and tumor detection rate; and (2) validity indicatorsdsensitivity,
specificity, positive, and negative predictive values for detecting colorectal neoplasms.
Results: A total of 10,563 and 1481 individuals were enrolled in PPS and HPS, respectively. Among quality indicators, there was no statistically
significant difference in the cecum reaching rate between PPS and HPS. The compliance rates were 56.1% for PPS and 91.8% for HPS
( p < 0.001). The advanced adenoma detection rates of PPS and HPS were 1.0% and 3.6%, respectively ( p < 0.01). The carcinoma detection
rates were 0.3% and 0.4%, respectively ( p ¼ 0.59). For validity indicators, PPS provides only a positive predictive value for colorectal tumor
detection. HPS provides additional validity indicators, including sensitivity, specificity, positive predictive value, and negative predictive value,
for colorectal tumor screening.
Conclusion: In comparison with the outcomes of the HPS database, the screening efficacy of the PPS database is even for detecting colorectal
carcinoma but is limited in detecting advanced adenoma. HPS may provide comprehensive validity indicators and will be helpful in adjusting
current policies for improving screening performance.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Colorectal cancer (CRC) accounts for the highest number of
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http://dx.doi.org/10.1016/j.jcma.2013.02.004cancer deaths in Taiwan.1,2 Most CRC develops via the well-
known adenomaecarcinoma sequence that averages 10e15
years for evolution.3,4 The generally slow rate of progression
provides the possibility for clinicians to reduce mortality and
morbidity of CRC by detecting neoplasms in the precancerous or
early stages through adequate screening for the average-risk
population.5 Currently, there are two main options for CRC
screening in the average-risk population, stool tests and endo-
scopic exams. Growing evidence suggests applying these optionshinese Medical Association. All rights reserved.
326 P.-H. Wu et al. / Journal of the Chinese Medical Association 76 (2013) 325e329in a systematic program of periodic screening has the potential to
significantly reduce deaths from CRC.6
The Taiwan Bureau of National Health Insurance began
population-based CRC detection programs in 2006 for people
between the ages of 50 years and 69 years using the immu-
nochemical fecal occult blood test (iFOBT) screening for
detecting asymptomatic CRC.7 This policy was extended to all
medical centers in Taiwan and was modified to be a com-
munityehospital collaboration model in 2010, but little is
known about its effectiveness. In this report, we present our
data evaluating the performance and outcomes of this public
policy and discuss its prospects by comparing it with the
current hospital-based health promotion service.
2. Methods2.1. Comparable databases and strategies for colorectal
tumor detectionWe compared two databases compiled in one medical center.
The “policy-promoted cancer screeningprogram” (PPS) database
was designed on the basis of the policies of the Taiwan Bureau of
National Health Insurance for screening of four types of cancers
highly prevalent in Taiwan, including oral cancer, breast cancer,
cervical cancer, and CRC. Strategies for CRC detection in PPS
are limited to average-risk individuals who are asymptomatic and
between the ages of 50 years and 69 years.We applied the iFOBT
(Kyowa, Tokyo, Japan or Eiken, Tokyo, Japan) screening for all
participants in the PPS group. Colonoscopic examination was
performed for people with positive iFOBT results. If a polyp was
observed, polypectomywas applied to obtain histological results.
The information available in CRC screening datasets of PPS
include age, gender, health style, geographical data, screening
tool, confirmed tool, and histological reports. The “health pro-
motion service” (HPS) database was designed to provide health
education, disease prevention, detection, and long-term follow-
up for a variety of populations. The fields in the HPS database are
more comprehensive and include age, gender, geographical, so-
cial, and medical records data. Similar to our previous report,
strategies for detecting CRC in HPS were administered to a wide
spectrum of participants who were volunteers from the commu-
nity or employees of companies with self-paid health check-ups,
and included a combination of iFOBT and colonoscopy exami-
nation.8 Polypectomy was performed if adenoma was observed
during colonoscopic examination.2.2. Participants and definitionsFig. 1. Flowchart of study participants of PPS and HPS. HPS ¼ health pro-
motion service; iFOBT ¼ immunochemical fecal occult blood test;
PPS ¼ policy-promoted screening.We retrospectively analyzed data from the two databases
from January to October 2010. To compare these databases, we
filteredHPS data by age. Participants aged between 50 years and
69 years were enrolled in the analysis. A comparison of out-
comes between the two strategies was divided into a quality
dimension and a validity dimension. In the quality dimension,
we calculated the compliance rate, cecum reaching rate, and
tumor detection rate of colonoscopy for PPS and HPS. Incom-
plete examinations due to very poor colon preparation wereexcluded. Colonoscopic compliance rates of PPS and HPS were
determined by number of colonoscopies/number of iFOBT
positive stools and number of people undergoing both iFOBT
and colonoscopy/number of people attending health check-ups,
respectively. Cecal intubation rate was defined as the number of
photographic documentations of the cecal landmark/number of
colonoscopies). The tumor detection rate was calculated as the
number of cases with tumors/the total number of participants.
We classified colorectal tumor as a polyp, advanced adenoma, or
carcinoma. A polyp was defined according to colonoscopic
finding regardless of the size and histological characteristics.
Advanced adenoma was defined by the presence of any of the
following histological or gross findings: villous adenoma, high-
grade dysplasia, and diameter of adenoma >1 cm.9 Carcinoma
was defined according to histological diagnosis. In the validity
dimension, we evaluated the sensitivity, specificity, positive
predictive value (PPV), and negative predictive value (NPV) of
iFOBT to detect polyps, advanced adenoma, and carcinoma in
the PPS and HPS by using per-protocol analysis and with the
intention to treat the cancer. All statistical analyses were con-
ducted using SAS software (SAS program forWindows, version
9.1.3; SAS institute Inc., Cary, NC, USA) to compare the two
databases. The differences between groups were assessed by
two-tailed Student t test and Chi-square test. A p value of<0.05
was considered to be statistically significant. The hospital ethics
committee approved this study. The Institutional Review Board
(IRB) number of this study was 95E-056.
3. Results3.1. Demographic characteristicsA total of 10,563 asymptomatic individuals aged between
50 years and 69 years attended the PPS program between
January and October 2010. There were 3106 individuals in the
HPS group. After filtration by age, 1481 participants aged
between 50 years and 69 years were enrolled for subsequent
Table 2
Comparison of quality indicators between PPS and HPS.
PPS HPS p
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measurements of the two groups, including age, gender,
screening tool, and policy, are shown in Table 1.(n ¼ 10,563) (n ¼ 1481)
Compliance rate of colonoscopy 56.1% 91.8% <0.001
a
3.2. Quality dimensionCecum reaching rate of colonoscopy 98.9% 96.6% NA
Tumor detection rate for:
Polyp 3.6% 26.9% <0.001
Advanced adenoma 1.0% 3.6% <0.001
Adenocarcinoma 0.3% 0.4% 0.59
HPS ¼ health promotion service; iFOBT ¼ immunochemical fecal occult
blood test; PPS ¼ policy-promoted screening.
a Both values are >95%, reflecting satisfactory quality.For the PPS group, the compliance rate of colonoscopy was
56.1% (669/1192). The cecal intubation rate was 98.8% (661/
669). In all individuals willing to participate in the national
CRC screening program, the tumor detection rates for polyp,
advanced adenoma, and adenocarcinoma were 3.6% (383/
10,563), 1.0% (107/10,563), and 0.3% (30/10,563), respec-
tively. In the HPS group, the compliance rate was 91.8%
(1359/1481), and the cecal intubation rate was 96.6% (1313/
1359). Among the 1481 participants, the tumor detection rates
for polyp, advanced adenoma, and adenocarcinoma were
26.9% (398/1481), 3.6% (53/1481), and 0.4% (6/1481),
respectively. Differences between the PPS and HPS groups in
these quality indicators are listed in Table 2.3.3. Validity dimensionDue to limitations of the screening policy, we were only
able to calculate the PPV of the PPS group by using the
samples as per the screening protocol (n ¼ 669). The PPV for
polyps, advanced adenoma, and adenocarcinoma were 57.2%
(383/669), 16.0% (107/669), and 4.5% (30/669), respectively.
In the HPS group, both iFOBT and colonoscopy were provided
to participants. We calculated the validity indicators for
iFOBT in individuals who adhered to the protocol (n ¼ 1359).
The sensitivity, specificity, PPV, and NPV for detecting colo-
rectal polyps were 22.5% (80/356), 90.2% (905/1003), 44.9%
(80/178), and 76.6% (905/1181), respectively. The sensitivity,
specificity, PPV, and NPV for detecting advanced adenoma
were 45.7% (21/46), 88.0% (1156/1313), 11.8% (21/178), and
97.9% (1156/1181), respectively. The sensitivity, specificity,
PPV, and NPV for detecting adenocarcinoma were 83.3% (5/
6), 87.2% (1180/1353), 2.8% (5/178), and 99.9% (1180/1181),
respectively. Differences in these validity indicators between
the PPS and HPS are listed in Table 3.
4. Discussion
Several population-based studies suggest that screening of
colorectal neoplasms using iFOBT can reduce mortality.Table 1
Demographic characteristics and screening policies of PPS and HPS.
PPS (n ¼ 10,563)
Aim Singleddetection of colorectal tumor
Population Average-risk population from the com
Fee National health insurance
Strategy for colorectal tumor screening Two-step (iFOBT(þ)/ colonoscopy
Positive rate of iFOBT 11.3%
Age (y) 50e69 (mean: 58)
Gender (M:F) 49%:51%
HPS ¼ health promotion service; iFOBT ¼ immunochemical fecal occult blood tSeveral countries have applied these results with some modifi-
cation to strategies for CRC screening.10e13 Despite its wide-
spread use, little is known regarding the validity of iFOBT in
colorectal neoplasia screening outcomes. In this study, we
evaluated two databases in which the iFOBTwas conducted for
asymptomatic, average-risk individuals aged between 50 years
and 69 years. These databases are independent and use different
screening protocols. By comparing their outcomes, we can un-
derstand the benefits and limitations of these two strategies
commonly used for detecting colorectal tumors.
Upon examining the quality dimensions of these two groups,
some key indicators showed significant differences. The
compliance rate for colonoscopy was 91.7% in the HPS group.
The high compliance rate is primarily due to the one-step
screening designdboth iFOBT and colonoscopy are included
in the examination set. In the PPS group, the compliance with
colonoscopy in participants whowere positive in the iFOBTwas
56.1%. Increasing compliance with colonoscopy clearly
enhanced screening performance and may have further reduced
CRC mortality. Factors influencing compliance rates may
include geographical remoteness,14 educational attainment,15
cleaning agents used for colonoscopy,16 and the physician’s
alertness.17,18 Additional effort should be made to improve
public awareness on the benefits of adhering to screening pro-
tocols. The colorectal neoplasm detection rate is another
important quality indicator for PPS and HPS. Our analysis
revealed that participants in the HPS group exhibited a much
higher polyp detection rate and advanced adenoma detection
rate than those in the PPS group (26.9% vs. 3.6%, p< 0.05; and
3.5% vs. 1.0%, p < 0.05), but the difference in detecting car-
cinoma was not significant between the two groups (Table 2).
These results reflect the differences in screening designs andHPS (n ¼ 1481) p
Multipledincluding detection of colorectal tumor NA




) One-step (combine iFOBT and colonoscopy) NA
12.0% 0.88
50e69 (mean: 57) 0.12
55%:45% 0.40
est; PPS ¼ policy-promoted screening.
Table 3
Comparison of validity indicators between PPS and HPS.
Detection of polyp Detection of advanced adenoma Detection of adenocarcinoma
PPS (n ¼ 669) HPS (n ¼ 1359) PPS (n ¼ 669) HPS (n ¼ 1359) PPS (n ¼ 669) HPS (n ¼ 1359)
Sensitivity d 22.4% d 45.6% d 83.3%
Specificity d 90.2% d 88.0% d 87.2%
PPV 57.2%* 44.9% 16.0%** 11.8% 4.5%*** 2.8%




HPS ¼ health promotion service; NPV ¼ negative predictive value; PPS ¼ policy-promoted screening; PPV ¼ positive predictive value.
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suggested that current PPS strategies are not satisfactory for
detecting advanced adenoma. Because most CRCs develop
through the adenomaecarcinoma sequence,3 setting a screening
end point for detecting advanced adenoma is reasonable. The
most effective method for improving the power of PPS for
identifying advanced adenoma remains to be elucidated.
The validity dimension is very helpful for understanding the
efficacy of the screening program. Similar to other population-
based studies, PPS can only provide a PPV for iFOBT in
detecting colorectal tumors.12,19,20 The PPV of PPS in the
screening of colorectal advanced adenoma and carcinoma are
small, and many positive results may be false positives. There-
fore, in the PPS group, we conducted colonoscopy for
iFOBT(þ) participants. However, PPS was not able to make
suggestions for thosewith iFOBT(e) or poor compliance (Table
3). Taking the advantage of the design of HPS, we can easily
calculate other key validity indicators, including the sensitivity,
specificity, PPV, and NPV, of iFOBT in detecting colorectal
neoplasms (Table 3). As false negative results may affect the
performance of the screening program, these results can provide
a valuable estimate of the false negative results in PPS. Addi-
tionally, these estimations may contribute to the understanding
of limitations in population-based screening and may indicate
reliable suggestions for individuals testing negative.
Our study has several limitations. Firstly, a population bias
may exist even with adjustment for age. Compared with PPS,
participants in the HPS group may have a higher socioeconomic
status, pay more attention to their health, and may enjoy a better
lifestyle; therefore, the incidence of colorectal neoplasms may
be different. Secondly, the number of individuals in the HPS
groupwas small, and therefore, the power of the study is limited.
Thirdly, we did not perform a cost-effectiveness analysis.
In conclusion, compared with the outcomes of the HPS,
the screening efficacy of the PPS is similar in detecting
colorectal carcinoma, but is limited in detecting advanced
adenoma. Additionally, HPS may provide a greater number
of validity indicators and can be applied to modify current
national screening strategies for improving screening
performance.
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